Modi'in Makabim-Re'ut, Israel · Founded 2005 · Privately Held (backing)
Developer of a cancer drug intended to activate immune responses by converting cancer camouflage into beacons for the immune system to attack. KAHR Bio is based in Modi'in Makabim-Re'ut, Israel and was founded in 2005. Its last reported valuation was $166 million in Nov 2022. It has raised $183 million.
Last reported valuation
$165.7M
Oct 2026
Priced at
—
Total raised
$183.3M
Last round
—
Cap table — not yet on record
KAHR Bio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of KAHR Bio with a free account
·The complete investor list: 19 names
·Watch KAHR Bio: the Monday email on marks, rounds and moves
